PDF, Patent Landscape Report on Atazanavir - WIPO

More documents

Recommendations

Info

TWO DRUGS DIRECTED AT DIFFERENT TARGETSAnother way to fight an agent like a virus is to attack it at different steps of the viral lifecycle, including viral uptake by cells, entry of viral nucleic acids or proteins into thereplication, transcription, or translation processes they require, viral assembly proteins likeHIV protease, and processes for exit from the cell. Integrase inhibitors prevent integration ofviral coding regions into the DNA of the host cell. In the example in Figure 39, the integraseinhibitor treatment is performed in combination with an inhibitor of other targets, one ofwhich is HIV protease.Figure 39 Multi-Target Combination44
Citations to this document mainly come from Bristol-Myers Squibb itself, and from Takedaand Merck (Angeletti). In Figure 40, all the nodes with red borders mention Atazanavir byname, and as in the case of the record shown, are discussing cocktails of drugs withmultiple targets. The Takeda applications do not mention Atazanavir, and instead they aretargeting dipeptidyl peptidase as a means to interfere with various other disease entities.Takeda acquired at least one of its lead compounds by acquisition of Syrrx Inc.Figure 40 Citations to the Integrase Combination <strong>Patent</strong>45
Page 4 and 5: ContentsSECTION 1: THE TWO OBJECTIV
Page 7 and 8: collection for nuggets of intellige
Page 9 and 10: CHEMICAL NAMINGChemical naming conv
Page 11 and 12: Figure 2: Legal Status for Novartis
Page 13 and 14: name, but after the patent protecti
Page 15 and 16: STAGE TWO CLINICAL SEARCHTo be more
Page 17 and 18: CLINICAL COLLECTIONThis is an examp
Page 19 and 20: THE FOUNDER PATENT AND ITS DOWNSTRE
Page 21 and 22: CHEMICAL COLLECTIONThis is an examp
Page 23 and 24: SECTION 5: GENERAL OVERVIEW OF THE
Page 25 and 26: FAMILY MEMBER COUNTRIESLooking at p
Page 27 and 28: The crossover between categories is
Page 29 and 30: THE DEVELOPER’S OWN TIMELINEThe A
Page 31 and 32: Several of the representative paten
Page 33 and 34: Figure 25. Emphasis Matrix for Sele
Page 35 and 36: PATENT QUALITY INDICATORS FOR SELEC
Page 37 and 38: Figure 30. References made by the F
Page 39 and 40: FORMULATIONSEven before a drug is a
Page 41 and 42: Figure 34. References to Bristol My
Page 43 and 44: PROPRIETARY DRUGS AND LITIGATIONThe
Page 45: TWO DRUGS DIRECTED AT THE SAME TARG
Page 49 and 50: USING OVERLAP TO FIND COMBINATIONS
Page 51 and 52: INTERNATIONAL PATENT CLASSIFICATION
Page 53 and 54: ased on the IPC, but with sometimes
Page 55 and 56: DERWENT MANUAL CODESDWPI Manual Cod
Page 58: For more information contact WIPO a

PDF, Patent Landscape Report on Atazanavir - WIPO

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?